Breast cancer in a transgender man and hypofractionated radiotherapy: A case report and review of literature

A 77-year-old transgender man (assigned female sex at birth, gender identity male, i.e. female-to-male) was referred for a palpable mass of the right chest wall. Biopsies revealed invasive lobular breast carcinoma. After discussion by a multidisciplinary tumour board meeting, the patient was treated...

Full description

Saved in:
Bibliographic Details
Published in:Cancer radiothérapie 2024-06, Vol.28 (3), p.272-274
Main Authors: Bennassi, A., Rivin Del Campo, E., Théodore, C., Huguet, F.
Format: Article
Language:English
Subjects:
Aged
Breast cancer
Breast Neoplasms - pathology
Breast Neoplasms - radiotherapy
Breast Neoplasms - surgery
Breast Neoplasms, Male - pathology
Breast Neoplasms, Male - radiotherapy
Breast Neoplasms, Male - surgery
Cancer du sein
Carcinoma, Lobular - pathology
Carcinoma, Lobular - radiotherapy
Female
Humans
Hypofractionated radiation therapy
Male
Mastectomy
Radiation Dose Hypofractionation
Radiotherapy, Adjuvant
Radiothérapie hypofractionnée
Transgender Persons
Transgenre
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 77-year-old transgender man (assigned female sex at birth, gender identity male, i.e. female-to-male) was referred for a palpable mass of the right chest wall. Biopsies revealed invasive lobular breast carcinoma. After discussion by a multidisciplinary tumour board meeting, the patient was treated with total mastectomy, adjuvant hypofractionated radiation therapy, and hormone therapy. At 1.5-year follow-up, there was no sign of recurrence or long-term radiation side effects. To our knowledge, this is the first reported case of adjuvant hypofractionated radiation therapy in a transgender patient with breast cancer. Un patient transgenre de 77ans s’est présenté avec une masse de la paroi thoracique droite. Les biopsies ont montré un carcinome lobulaire invasif mammaire. Après discussion en réunion de concertation pluridisciplinaire, le patient a eu une mastectomie totale, une radiothérapie hypofractionnée adjuvante et une hormonothérapie adjuvante. À 1,5ans de suivi, le patient ne présentait ni rechute ni d’effets indésirables tardifs. À notre connaissance, il s’agit du premier cas décrit de radiothérapie hypofractionnée adjuvante chez un patient transgenre.
ISSN:1278-3218
1769-6658
1769-6658
DOI:10.1016/j.canrad.2023.08.011